A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma
J. Erika Haydu(Brigham and Women's Hospital), Jeremy S. Abramson(Massachusetts General Hospital), Ronald W. Takvorian(Massachusetts General Hospital), Lakshmi Nayak(Dana-Farber Cancer Institute), Isabel Arrillaga‐Romany(Harvard University), Jeffrey A. Barnes(Harvard University), J Ricardo McFaline-Figueroa(NYU Langone Health), Ephraim P. Hochberg(Massachusetts General Hospital), Philipp Karschnia(Harvard University), Caron A. Jacobson(Dana-Farber Cancer Institute), Matthew Lei(Massachusetts General Hospital), April F. Eichler(Beth Israel Deaconess Medical Center), Jörg Dietrich(Massachusetts General Hospital), Philippe Armand(Harvard University), Ugonma Chukwueke, Justin T. Jordan(Massachusetts General Hospital), Scott R. Plotkin(Massachusetts General Hospital), P. Connor Johnson(Harvard University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Jacob D. Soumerai(Harvard University), Robert Redd(Harvard University)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595